CompletedNot Applicable

Influence of Enteral Microbiome on Mortality of Patients With Cardiogenic Shock

Germany40 participantsStarted 2023-08-30

Plain-language summary

Cardiogenic shock is associated with a high mortality. The microbiome is a double-edged sword which can convey protective and detrimental cardiovascular effects. The significance of the enteral micobiome on cardiovascular mortality of patients with cardiogenic shock is still not known. This study aims to provide a deeper understanding of the role of the enteral microbiome and microbiome dependent metabolites in mortality and disease progression of patients with cardiogenic shock.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * \>18y * signs of cardiogenic shock regardless of etiology * lactate \>3mmol/L * and signs of organ dysfunction (urine output \<30 ml/h, cold extremities, altered mental status) * and systolic blood pressure \<90 mmHg for \>30 minutes or need for vasopressor therapy Exclusion Criteria: * pregnancy/lactation period * antibiotic treatment within \>24h * chronic inflammatory bowel disease * short bowel syndrome * artificial bowel outlet * persistent diarrhea or vomiting in the past 3 months * simultaneous participation in another interfering nutrition study * active chemo or radiation therapy

What they're measuring

Correlation between enteral microbiome composition and mortality

Timeframe: Sampling will be performed within 24 hours of onset of cardiogenic shock and clinical evaluation will be performed after 1 month

Trial details

NCT IDNCT06006754

SponsorUniversity Hospital, Essen

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-08-15

View on ClinicalTrials.gov More Cardiogenic Shock trials